Evogene Ltd.于4月2日宣布,公司已收到纳斯达克交易所发出的最低买入价合规通知。该通知指出,Evogene的普通股在连续30个交易日内收盘价低于每股1.00美元,未达到纳斯达克上市规则规定的最低买入价要求。
根据纳斯达克相关规定,Evogene拥有180天的宽限期,即至2026年9月30日前,若公司股价能连续10个交易日收盘价达到或超过1.00美元,则将重新符合上市标准。在此期间,Evogene的股票将继续在纳斯达克交易,代码维持为"EVGN"。
公司表示将积极监控股价情况,并评估可行方案以恢复合规状态。目前,Evogene的业务运营未受此通知影响,各项研发项目按计划推进。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.